TRANSCODE THERAPEUTICS INC
RNAZNASDAQ🏆 #3914 by market capUS Equity
$589.19▼ $18.68 (−3.17%)
Simulated price1h—
24h▼ 3.2%
7d▲ 11122.7%
14d▲ 12200.4%
30d▲ 6523.8%
1y▲ 5082.0%
🏦Market Cap
$4M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
49
Weak
Trading Snapshot
- Day Range
- $587.40 – $592.95
- 52-Week Range
- $3.82 – $20.99
- Volume
- $3.17B
- Avg Volume
- $2.73B
- Shares Outstanding
- 1.1M
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $307,677
- Last Q Revenue
- $83,304
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-45.07
- Dividend Yield
- —
Why Investors Own RNAZ
- ✓High-growth profile — revenue up +39.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$307,677▲ +32.9% YoY
Gross Margin (TTM)
67.1%▲ +1.9% YoY
Operating Income (TTM)
$66,766▲ +32.9% YoY
Free Cash Flow (TTM)
$41,844▲ +32.9% YoY
About TRANSCODE THERAPEUTICS INC
A company profile for TRANSCODE THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
49/100
Analyst Price Target
ⓘAverage Target
$721.45
▲ +22.4% Upside
High Target$860.95
Low Target$568.83
Based on 24 analysts
Latest News & Updates
🚀
Reuters·2h ago
TRANSCODE THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift RNAZ price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
TRANSCODE THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.